Remibrutinib
Sign in to save this workspacePrimary targets: BTK · FDA status: FDA Phase III Trials
Selectivity scorecard
KISS
99.50
Gini
0.721
CATDS
0.076
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Remibrutinib. Strongest target: BTK at 97.7% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | BTK | 97.7% | 2.3% |
| 2 | BMX_ETK | 91.9% | 8.1% |
| 3 | TEC | 71.9% | 28.1% |
| 4 | SGK2 | 22.5% | 77.5% |
| 5 | PKN3_PRK3 | 20.1% | 79.9% |
| 6 | TYK2 | 16.2% | 83.8% |
| 7 | P38D_MAPK13 | 14.9% | 85.1% |
| 8 | MST4 | 13.7% | 86.3% |
| 9 | LCK2_ICK | 13.1% | 86.9% |
| 10 | ROCK1 | 13.1% | 86.9% |
| 11 | IKKE_IKBKE | 12.8% | 87.2% |
| 12 | NEK3 | 12.3% | 87.7% |
| 13 | TXK | 11.8% | 88.2% |
| 14 | PKG1B | 11.0% | 89.0% |
| 15 | WNK3 | 10.6% | 89.4% |
| 16 | RIPK2 | 10.5% | 89.5% |
| 17 | CDK2_CYCLIN_A1 | 10.5% | 89.5% |
| 18 | CAMKK1 | 10.3% | 89.8% |
| 19 | PAK6 | 10.2% | 89.8% |
| 20 | MKK6 | 10.1% | 89.9% |
Selectivity landscape
Where Remibrutinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Remibrutinib.
Annotations
Sign in to read and post annotations.
Loading…